Literature DB >> 1407898

Should women with familial ovarian cancer undergo prophylactic oophorectomy?

K Kerlikowske1, J S Brown, D G Grady.   

Abstract

OBJECTIVES: To estimate the lifetime probabilities of ovarian cancer in women from families with hereditary ovarian cancer syndromes and those with a family history of ovarian cancer, and to assess the needs for prevention and surveillance in such women. DATA SOURCES: We searched for studies of familial ovarian cancer published since 1966 and used ovarian cancer incidence data from the Surveillance, Epidemiology, and End Results program of the National Cancer Institute.
METHODS: Pooled estimates of relative risk of ovarian cancer among women with a family history of ovarian cancer were derived using statistical methods based on fixed effects. Modified life-table methods were used to estimate the lifetime probability of ovarian cancer. DATA SYNTHESIS: The lifetime probability of ovarian cancer increases from about 1.6% in a 35-year-old woman without a family history of ovarian cancer to about 5% if she has one relative and 7% if she has two relatives with ovarian cancer. The lifetime probability may decrease to about 3-4% if she takes oral contraceptives for 5-9 years. Women from families with hereditary ovarian cancer syndromes may have as high as a 50% lifetime risk of ovarian cancer.
CONCLUSIONS: The risk of ovarian cancer in women from families with hereditary ovarian cancer syndromes is sufficiently high to warrant prophylactic oophorectomy. Among women with one relative with ovarian cancer, the lifetime probability of ovarian cancer is not high enough to recommend oophorectomy. However, some women may choose oophorectomy depending on their attitudes concerning risk-taking, surgery, and hormone replacement. Oral contraceptives should be considered as preventive therapy to decrease the risk of ovarian cancer in women with a family history of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1407898

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  13 in total

Review 1.  Forth nightly review: hereditary ovarian carcinoma.

Authors:  L Kasprzak; W D Foulkes; A N Shelling
Journal:  BMJ       Date:  1999-03-20

2.  Screening for ovarian cancer: recommendation statement.

Authors: 
Journal:  Ann Fam Med       Date:  2004 May-Jun       Impact factor: 5.166

3.  Can you screen for ovarian cancer?

Authors:  M L Hicks; G Parham
Journal:  J Natl Med Assoc       Date:  1995-02       Impact factor: 1.798

4.  Choice of management of southern Chinese BRCA mutation carriers.

Authors:  Ava Kwong; Connie H N Wong; Catherine Shea; Dacita T K Suen; Catherine L Y Choi
Journal:  World J Surg       Date:  2010-07       Impact factor: 3.352

5.  Family history in ovarian cancer referral population.

Authors:  L A Berg; S Robert Young; K A Brooks; A M Davis; S Terry Smith
Journal:  J Genet Couns       Date:  1996-03       Impact factor: 2.537

Review 6.  Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today?

Authors:  D E Cole; S Gallinger; D R McCready; B Rosen; J Engel; D Malkin
Journal:  CMAJ       Date:  1996-01-15       Impact factor: 8.262

Review 7.  Referral for cancer genetics consultation: a review and compilation of risk assessment criteria.

Authors:  H Hampel; K Sweet; J A Westman; K Offit; C Eng
Journal:  J Med Genet       Date:  2004-02       Impact factor: 6.318

8.  Accuracy of ovarian and colon cancer risk assessments by U.S. physicians.

Authors:  Laura-Mae Baldwin; Katrina F Trivers; C Holly A Andrilla; Barbara Matthews; Jacqueline W Miller; Denise M Lishner; Barbara A Goff
Journal:  J Gen Intern Med       Date:  2014-02-12       Impact factor: 5.128

9.  Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients.

Authors:  Paulette Mhawech-Fauceglia; Dan Wang; Liaquat Ali; Shashikant Lele; Michael A Huba; Song Liu; Kunle Odunsi
Journal:  Cancer Immun       Date:  2013-01-15

10.  A sociobehavioural perspective on genetic testing and counselling for heritable breast, ovarian and colon cancer.

Authors:  K G Macdonald; B Doan; M Kelner; K M Taylor
Journal:  CMAJ       Date:  1996-02-15       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.